The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Breast cancer statistics, 2019
Open accessAbstract
This article is the American Cancer Society’s biennial update on female breast cancer statistics in the United States, including data on incidence, mortality, survival, and screening. Over the most recent 5‐year period (2012‐2016), the breast cancer incidence rate increased slightly by 0.3% per year, largely because of rising rates of local stage and hormone receptor‐positive disease. In contrast, the breast cancer death rate continues to decline, dropping 40% from 1989 to 2017 and translating to 375,900 breast cancer deaths averted. Notably, the pace of the decline has slowed from an annual decrease of 1.9% during 1998 through 2011 to 1.3% during 2011 through 2017, largely driven by the trend in white women. Consequently, the black–white disparity in breast cancer mortality has remained stable since 2011 after widening over the past 3 decades. Nevertheless, the death rate remains 40% higher in blacks (28.4 vs 20.3 deaths per 100,000) despite a lower incidence rate (126.7 vs 130.8); this disparity is magnified among black women aged <50 years, who have a death rate double that of whites. In the most recent 5‐year period (2013‐2017), the death rate declined in Hispanics (2.1% per year), blacks (1.5%), whites (1.0%), and Asians/Pacific Islanders (0.8%) but was stable in American Indians/Alaska Natives. However, by state, breast cancer mortality rates are no longer declining in Nebraska overall; in Colorado and Wisconsin in black women; and in Nebraska, Texas, and Virginia in white women. Breast cancer was the leading cause of cancer death in women (surpassing lung cancer) in four Southern and two Midwestern states among blacks and in Utah among whites during 2016‐2017. Declines in breast cancer mortality could be accelerated by expanding access to high‐quality prevention, early detection, and treatment services to all women.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160
Self-citationSiegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,579
Self-citationWriting Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Cancer treatment and survivorship statistics, 2016
Miller, K. D., Siegel, R. L., Lin, C. C., Mariotto, A. B., Kramer, J. L., Rowland, J. H., Stein, K. D., Alteri, R., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21349 · Cited by 6,066
Self-citationBreast Cancer Treatment: A Review
Waks, A. G., & Winer, E. P. (2019) · JAMA · doi:10.1001/jama.2018.19323 · Cited by 4,804
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Cancer treatment and survivorship statistics, 2019
Miller, K. D., Nogueira, L., Mariotto, A. B., Rowland, J. H., Yabroff, K. R., Alfano, C. M., Jemal, A., Kramer, J. L., & Siegel, R. L. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21565 · Cited by 4,226
Self-citationScreening for Lung Cancer: U.S. Preventive Services Task Force Recommendation Statement
Moyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2014) · Annals of Internal Medicine · doi:10.7326/m13-2771 · Cited by 2,632
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
von Minckwitz, G., Huang, C.-S., Mano, M. S., Loibl, S., Mamounas, E. P., Untch, M., Wolmark, N., Rastogi, P., Schneeweiss, A., Redondo, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814017 · Cited by 2,625
Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer
Berry, D. A., Cronin, K. A., Plevritis, S. K., Fryback, D. G., Clarke, L., Zelen, M., Mandelblatt, J. S., Yakovlev, A. Y., Habbema, J. D. F., & Feuer, E. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050518 · Cited by 2,460
Research works printed but not linked: 16
- Surveillance, Epidemiology, and End Results (SEER) Program, 2019, SEER*Stat Database: Incidence‐SEER 9 Regs Research Data with Delay‐Adjustment, Malignant Only, based on the November 2018 submission
- Surveillance Epidemiology and End Results (SEER) Program.Breast Schema for 1988‐2015 Based on AJCC 6th Edition. Accessed August 8 2019.seer.cancer.gov/seerstat/variables/seer/ajcc-stage/6th/breast.html
- Surveillance, Epidemiology, and End Results (SEER) Program, 2019, SEER*Stat Database: Incidence‐SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2018 Submission (2000‐2016) <Katrina/Rita Population Adjustment>‐Linked To County Attributes‐Total U.S., 1969‐2017 Counties
- Surveillance, Epidemiology, and End Results (SEER) Program, 2018, SEER*Stat Database: North American Association of Central Cancer Registries (NAACCR) Incidence Data‐Cancer in North America (CiNA) Analytic File, 1995‐2015, for NHIAv2 Origin, Custom File With County, American Cancer Society (ACS) Facts and Figures Projection Project (which includes data from the Centers for Disease and Prevention's [CDC's] National Program of Cancer Registries [NPCR], the Canadian Council of Cancer Registry's [CCCR's] Provincial and Territorial Registries, and the National Cancer Institute's [NCI's] SEER Registries)
- Surveillance, Epidemiology, and End Results (SEER) Program, 2018, SEER*Stat Database: North American Association of Central Cancer Registries (NAACCR) Incidence Data‐Cancer in North America (CiNA) Analytic File, 1995‐2016, for Expanded Races, Custom File With County, American Cancer Society (ACS) Facts and Figures Projection Project (which includes data from the Centers for Disease and Prevention's [CDC's] National Program of Cancer Registries [NPCR], the Canadian Council of Cancer Registry's [CCCR's] Provincial and Territorial Registries, and the National Cancer Institute's [NCI's] SEER Registries)
- Surveillance, Epidemiology, and End Results (SEER) Program (seer.cancer.gov), SEER*Stat Database: Mortality ‐ All COD, Total U.S. (1969‐2017) <Early release with Vintage 2017 Katrina/Rita Population Adjustment> ‐ Linked To County Attributes ‐ Total U.S., 1969‐2017 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released May 2019. Underlying mortality data provided by NCHS (cdc.gov/nchs)
- Surveillance, Epidemiology, and End Results (SEER) Program, 2019, SEER*Stat Database: Mortality‐All COD, Aggregated With State, Total U.S. (1990‐2017) <Early release with Vintage 2017 Katrina/Rita Population Adjustment>
- American College of Surgeons Commission on Cancer, 2019, National Cancer Database, 2016 Data Submission
- Centers for Disease Control and Prevention, 2016, Behavioral Risk Factor Surveillance System Survey Data 2016
- Surveillance Research Program, National Cancer Institute, 2018, SEER*Stat Software. Version 8.3.5
- National Cancer Institute, 2019, Joinpoint Regression Program, Version 4.7.0.0
- National Cancer Institute, 2019, DevCan: Probability of Developing or Dying of Cancer Software, Version 6.7.7
- Howlader N, 2019, SEER Cancer Statistics Review, 1975‐2016. Based on the November 2018 SEER data submission, posted to the SEER website April 2019
- 10.1158/1055-9965.EPI-14-0624 · doi:10.1158/1055-9965.epi-14-0624
- Martin JA, 2018, Births: Final Data for 2017, Natl Vital Stat Rep., 67, 1
- 10.1245/s10434-018-6531-5 · doi:10.1245/s10434-018-6531-5
Cited by
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Self-citationSiegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Self-citationCancer treatment and survivorship statistics, 2022
Miller, K. D., Nogueira, L., Devasia, T., Mariotto, A. B., Yabroff, K. R., Jemal, A., Kramer, J., & Siegel, R. L. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21731 · Cited by 3,597
Self-citationCurrent and future burden of breast cancer: Global statistics for 2020 and 2040
Arnold, M., Morgan, E., Rumgay, H., Mafra, A., Singh, D., Laversanne, M., Vignat, J., Gralow, J. R., Cardoso, F., Siesling, S., et al. (2022) · The Breast · doi:10.1016/j.breast.2022.08.010 · Cited by 3,411
“Rising incidence rates have been reported in several high-income countries in North America, Europe and Oceania since 2007 for pre- and postmenopausal breast cancer [2,20].”
BackgroundLoibl, S., Poortmans, P., Morrow, M., Denkert, C., & Curigliano, G. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32381-3 · Cited by 1,648
Estimated Projection of US Cancer Incidence and Death to 2040
Rahib, L., Wehner, M. R., Matrisian, L. M., & Nead, K. T. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.4708 · Cited by 1,339
Cancer statistics for adolescents and young adults, 2020
Miller, K. D., Fidler‐Benaoudia, M., Keegan, T. H., Hipp, H. S., Jemal, A., & Siegel, R. L. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21637 · Cited by 1,190
Self-citationLei, S., Zheng, R., Zhang, S., Wang, S., Chen, R., Sun, K., Zeng, H., Zhou, J., & Wei, W. (2021) · Cancer Communications · doi:10.1002/cac2.12207 · Cited by 1,113
Epidemiological characteristics of and risk factors for breast cancer in the world
Momenimovahed, Z., & Salehiniya, H. (2019) · Breast Cancer: Targets and Therapy · doi:10.2147/bctt.s176070 · Cited by 1,050
Key steps for effective breast cancer prevention
Britt, K. L., Cuzick, J., & Phillips, K.-A. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0266-x · Cited by 992
Overcoming Endocrine Resistance in Breast Cancer
Hanker, A. B., Sudhan, D. R., & Arteaga, C. L. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.009 · Cited by 927
Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study
Heer, E., Harper, A., Escandor, N., Sung, H., McCormack, V., & Fidler-Benaoudia, M. M. (2020) · The Lancet Global Health · doi:10.1016/s2214-109x(20)30215-1 · Cited by 888
PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects
Miricescu, D., Totan, A., Stanescu-Spinu, I.-I., Badoiu, S. C., Stefani, C., & Greabu, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010173 · Cited by 845
Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities
Xu, X., Zhang, M., Xu, F., & Jiang, S. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01276-5 · Cited by 588
Cancer statistics for African American/Black People 2022
Giaquinto, A. N., Miller, K. D., Tossas, K. Y., Winn, R. A., Jemal, A., & Siegel, R. L. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21718 · Cited by 574
Self-citationCurrent advance of nanotechnology in diagnosis and treatment for malignant tumors
Wang, B., Hu, S., Teng, Y., Chen, J., Wang, H., Xu, Y., Wang, K., Xu, J., Cheng, Y., & Gao, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01889-y · Cited by 558
Annual report to the nation on the status of cancer, part 1: National cancer statistics
Cronin, K. A., Scott, S., Firth, A. U., Sung, H., Henley, S. J., Sherman, R. L., Siegel, R. L., Anderson, R. N., Kohler, B. A., Benard, V. B., et al. (2022) · Cancer · doi:10.1002/cncr.34479 · Cited by 557
Self-citationAdvances in systemic therapies for triple negative breast cancer
Leon-Ferre, R. A., & Goetz, M. P. (2023) · BMJ · doi:10.1136/bmj-2022-071674 · Cited by 507
Annual Report to the Nation on the Status of Cancer, Part 1: National Cancer Statistics
Islami, F., Ward, E. M., Sung, H., Cronin, K. A., Tangka, F. K. L., Sherman, R. L., Zhao, J., Anderson, R. N., Henley, S. J., Yabroff, K. R., et al. (2021) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djab131 · Cited by 478
Self-citationWang, R., Zhu, Y., Liu, X., Liao, X., He, J., & Niu, L. (2019) · BMC Cancer · doi:10.1186/s12885-019-6311-z · Cited by 459
Epidemiology of male breast cancer
Konduri, S., Singh, M., Bobustuc, G., Rovin, R., & Kassam, A. (2020) · The Breast · doi:10.1016/j.breast.2020.08.010 · Cited by 411
A Basic Review on Estrogen Receptor Signaling Pathways in Breast Cancer
Clusan, L., Ferrière, F., Flouriot, G., & Pakdel, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076834 · Cited by 382
HIFs, angiogenesis, and metabolism: Elusive enemies in breast cancer
de Heer, E. C., Jalving, M., & Harris, A. L. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137552 · Cited by 372
Epidemiology of Triple-Negative Breast Cancer: A Review
Howard, F. M., & Olopade, O. I. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000500 · Cited by 338
Global guidelines for breast cancer screening: A systematic review
Ren, W., Chen, M., Qiao, Y., & Zhao, F. (2022) · The Breast · doi:10.1016/j.breast.2022.04.003 · Cited by 325
Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments
Yip, H. Y. K., & Papa, A. (2021) · Cells · doi:10.3390/cells10030659 · Cited by 316
Yamazaki, C. M., Yamaguchi, A., Anami, Y., Xiong, W., Otani, Y., Lee, J., Ueno, N. T., Zhang, N., An, Z., & Tsuchikama, K. (2021) · Nature Communications · doi:10.1038/s41467-021-23793-7 · Cited by 309
Tumor organoids: applications in cancer modeling and potentials in precision medicine
Xu, H., Jiao, D., Liu, A., & Wu, K. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01278-4 · Cited by 286
Molecular Subtypes of Breast Cancer: A Review for Breast Radiologists
Johnson, K. S., Conant, E. F., & Soo, M. S. (2021) · Journal of Breast Imaging · doi:10.1093/jbi/wbaa110 · Cited by 280
Zou, Y., Ye, F., Kong, Y., Hu, X., Deng, X., Xie, J., Song, C., Ou, X., Wu, S., Wu, L., et al. (2023) · Advanced Science · doi:10.1002/advs.202203699 · Cited by 278
Mechanism of RNA modification N6-methyladenosine in human cancer
Zhou, Z., Lv, J., Yu, H., Han, J., Yang, X., Feng, D., Wu, Q., Yuan, B., Lu, Q., & Yang, H. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01216-3 · Cited by 275
Dekkers, J. F., van Vliet, E. J., Sachs, N., Rosenbluth, J. M., Kopper, O., Rebel, H. G., Wehrens, E. J., Piani, C., Visvader, J. E., Verissimo, C. S., et al. (2021) · Nature Protocols · doi:10.1038/s41596-020-00474-1 · Cited by 272
American Cancer Society's report on the status of cancer disparities in the United States, 2021
Islami, F., Guerra, C. E., Minihan, A., Yabroff, K. R., Fedewa, S. A., Sloan, K., Wiedt, T. L., Thomson, B., Siegel, R. L., Nargis, N., et al. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21703 · Cited by 264
Self-citationDelfi, M., Sartorius, R., Ashrafizadeh, M., Sharifi, E., Zhang, Y., De Berardinis, P., Zarrabi, A., Varma, R. S., Tay, F. R., Smith, B. R., et al. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101119 · Cited by 253
Initial Surgery and Survival in Stage IV Breast Cancer in the United States, 1988-2011
Thomas, A., Khan, S. A., Chrischilles, E. A., & Schroeder, M. C. (2016) · JAMA Surgery · doi:10.1001/jamasurg.2015.4539 · Cited by 176
Biomimetic hydrogel supports initiation and growth of patient-derived breast tumor organoids
Prince, E., Cruickshank, J., Ba-Alawi, W., Hodgson, K., Haight, J., Tobin, C., Wakeman, A., Avoulov, A., Topolskaia, V., Elliott, M. J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28788-6 · Cited by 135
Microfluidic Arrays of Breast Tumor Spheroids for Drug Screening and Personalized Cancer Therapies
Prince, E., Kheiri, S., Wang, Y., Xu, F., Cruickshank, J., Topolskaia, V., Tao, H., Young, E. W. K., McGuigan, A. P., Cescon, D. W., et al. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202101085 · Cited by 121
Sandbank, J., Bataillon, G., Nudelman, A., Krasnitsky, I., Mikulinsky, R., Bien, L., Thibault, L., Albrecht Shach, A., Sebag, G., Clark, D. P., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00496-w · Cited by 112
Ma, L., Wang, L., Nelson, A. T., Han, C., He, S., Henn, M. A., Menon, K., Chen, J. J., Baek, A. E., Vardanyan, A., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.08.020 · Cited by 98
Bower, J. E., Partridge, A. H., Wolff, A. C., Thorner, E. D., Irwin, M. R., Joffe, H., Petersen, L., Crespi, C. M., & Ganz, P. A. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00279 · Cited by 81
Lyu, M., Siah, R. C., Lam, A. S. L., & Cheng, K. K. F. (2022) · Journal of Advanced Nursing · doi:10.1111/jan.15321 · Cited by 77
The Multifaceted Role of Regulatory T Cells in Breast Cancer
Kos, K., & de Visser, K. E. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-042920-104912 · Cited by 58
Wang, J., Liang, S., Chen, S., Ma, T., Chen, M., Niu, C., Leng, Y., & Wang, L. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02619-w · Cited by 53
Imiquimod-gemcitabine nanoparticles harness immune cells to suppress breast cancer
Singh, B., Maharjan, S., Pan, D. C., Zhao, Z., Gao, Y., Zhang, Y. S., & Mitragotri, S. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2021.121302 · Cited by 49
Hand, T., Rosseau, N. A., Stiles, C. E., Sheih, T., Ghandakly, E., Oluwasanu, M., & Olopade, O. I. (2021) · Global Health Action · doi:10.1080/16549716.2021.1883336 · Cited by 47
Martini, R., Newman, L., & Davis, M. (2022) · Clinical & Experimental Metastasis · doi:10.1007/s10585-021-10087-x · Cited by 46
Self-citationDeng, X., Xie, B., Li, Q., Xiao, Y., Hu, Z., Deng, X., Fang, P., Dong, C., Zhou, H.-B., & Huang, J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00525 · Cited by 43
Huang, Y., Li, Q., Zhou, F., & Song, J. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-057664 · Cited by 36
Lengacher, C. A., Gruss, L. F., Kip, K. E., Reich, R. R., Chauca, K. G., Moscoso, M. S., Joshi, A., Tinsley, S., Shani, B., Cousin, L., et al. (2021) · Journal of Behavioral Medicine · doi:10.1007/s10865-021-00214-0 · Cited by 40
Jiang, C., Zhu, Y., Chen, H., Lin, J., Xie, R., Li, W., Xue, J., Chen, L., Chen, X., & Xu, S. (2023) · Cell Death & Disease · doi:10.1038/s41419-023-06181-5 · Cited by 36
Breast cancer: miRNAs monitoring chemoresistance and systemic therapy
Singh, S., Saini, H., Sharma, A., Gupta, S., Huddar, V. G., & Tripathi, R. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1155254 · Cited by 25
Qiu, L., Kanski, B., Doerksen, S., Winkels, R., Schmitz, K. H., & Abdullah, S. (2021) · Extended Abstracts of the 2021 CHI Conference on Human Factors in Computing Systems · doi:10.1145/3411763.3451827 · Cited by 23
Takeda, T., Tsubaki, M., Matsuda, T., Kimura, A., Jinushi, M., Obana, T., Takegami, M., & Nishida, S. (2022) · Oncology Reports · doi:10.3892/or.2022.8320 · Cited by 17
Younis, M., Norsa'adah, B., & Othman, A. (2021) · Breast Cancer: Targets and Therapy · doi:10.2147/bctt.s299584 · Cited by 17
“On one hand, the patients face unmet needs at the time of diagnosis and they often have the urge to speak with someone experienced to obtain the necessary information to overcome the disease.(2) On the other hand, physicians usually need to see a large number of patients in the clinics daily, putting them at a point o…”
BackgroundWright, A. (2021) · mHealth · doi:10.21037/mhealth-20-161 · Cited by 16
Shao, L., Liu, D., Liu, X., Wang, X., Yang, X., Niu, R., Yin, S., Xu, P., Mao, Y., Du, X., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117402 · Cited by 14
The Roles of Cloud-Based Systems on the Cancer-Related Studies: A Systematic Literature Review
Xu, B., & Zhou, F. (2022) · IEEE Access · doi:10.1109/access.2022.3181147 · Cited by 13
Rlip Depletion Suppresses Growth of Breast Cancer
Bose, C., Yadav, S., Singhal, S. S., Singhal, J., Hindle, A., Lee, J., Cheedella, N. K. S., Rehman, S., Layeequr Rahman, R., Jones, C., et al. (2020) · Cancers · doi:10.3390/cancers12061446 · Cited by 10
Wei, R., Dai, H., Zhang, J., Shih, D. J. H., Liang, Y., Xiao, P., McGrail, D. J., & Lin, S.-Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22095008 · Cited by 4
Metadata
- Authors
- DeSantis, C. E., Ma, J., Gaudet, M. M., Newman, L. A., Miller, K. D., Goding Sauer, A., Jemal, A., & Siegel, R. L.
- Venue
- CA: A Cancer Journal for Clinicians
- Publisher
- Wiley
- Published
- 2019-10-02
- Volume
- 69
- Issue
- 6
- Pages
- 438-451
- ISSN
- 0007-9235 (ISSN-L)
- 1542-4863
- OpenAlex
- W2979291688
- Cited by
- 3,114
- References
- 57
- FWCI
- 170.13
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.